Why team norms transform team dynamics

Do you know any leaders who accepted new opportunities, changed jobs, or joined as a new organization leader this year? Was that leader you? Great. I have some excellent tips for you.

Hi, I’m Peter Nichol, Data Science CIO.

Today we’re going to talk about team norms. The idea behind team norms is that every team has informal and formal ways to integrate, collaborate, and support behaviors that are encouraged by that team. The concept of team norms is to start with principles that the team generates themselves explicitly. This defines the behaviors the team promotes. By doing this, it helps focus the team on cooperative or accepted group behaviors.

Sure, as the leading executive, you can make a demand and say, “This is what we’re going to be doing.” Or, you can announce that these are the ideals, mantra, or ideology that the team will perform. But this approach doesn’t build joint ownership of any of those behaviors you just communicated. If you want to have co-ownership, you need collaboration in the development of those norms. Ultimately, it would help if you had input from your team and the leaders who’ll perform these behaviors and maintain these norms day-to-day. So how does this work?

Typically, we start with a roundtable session in which you discuss exemplary behavior. In a roundtable fashion, the group slowly develops a list of norms they’ll accept. By doing this, we establish how our team will perform and interact. This defines the dynamics of that team.

Starting in an organization as a new leader, you have an opportunity to change team interactions. Some of these interactions may be positive, and some may be negative. What’s relevant here is that we’re redefining how we want this team to interact for optimal performance. There are, of course, certain situations in which joining an existing high-performing team and offering up new norms doesn’t add a lot of utility.

However, when you pick a new team internally or join a new team externally, defining team norms is an excellent way to unify and establish a team performance baseline. Let’s discuss some examples of team norms. Examples of norms might be, “Treat others fairly,” or, “Be present,” or, “Be here now.” These norms are focused on engagement. If the team is in a meeting, electronic devices are put down, and the team stays focused. Suppose someone does need to respond to an email or check that voicemail. Not a problem—they step out of the meeting and check that email or take that call. When that individual can fully engage and give other team members the respect they deserve, they rejoin the discussion physically and mentally.

Another norm might be, “Respond to email promptly.” What does this mean? Is that 24 hours? Is it 72 hours? We need to define those norms clearly. What if you receive a voicemail? Should you pick that up in 24 hours, or is a couple of days, okay? Each team norm defines standards for baseline performance.

Team norms help the team understand what’s good performance and what’s not good performance. They also allow the team to challenge the leader or executive in a healthy way. Another norm might be, “You’re always able to challenge decisions respectfully.” So yes, we want a different and alternative opinion. Every opinion won’t be accepted all the time, but we want a complete set of data when making difficult executive decisions.

Here are examples of team norms I find useful:

  • Listen to understand.
  • Trust is everything.
  • Foster relationships.
  • Practice being open-minded.
  • Give colleagues the benefit of the doubt.
  • Respect the time and convenience of others.
  • Treat each other with dignity and respect.
  • Avoid hidden agendas.
  • Support each other; don’t throw each other under the bus.
  • It’s okay to ask for help; in fact, it’s encouraged.
  • Have direct conversations.
  • Be self-aware.
  • Celebrate accomplishments.
  • Raise each other up.
  • Think in terms of scale.
  • Take ownership.
  • Limit technology during meetings.
  • If you join, engage.
  • Don’t be afraid to challenge others respectfully.
  • One person talks at a time—no side discussions.
  • The goal isn’t to agree, it’s to build a group that has a diversity of experience; listen to alternatives.
  • If you’ll be absent, identify coverage (if possible).
  • Respond to email within 48 hours.
  • Respond to v-mail with 24 hours.

Establishing team norms can provide significant benefits to team dynamics. Hi, I’m Peter Nichol, Data Science CIO. Have a great day!

Biotech taking ownership of the whole supply chain

Usually, there is a lot of energy and money dedicated to speed to market, service effectiveness, and driving new business models. Typically, this is represented as breaking down silos, which might include:

  • Demand forecasting
  • Supply planning
  • Production manufacturing
  • Logistics planning
  • Sales and operations

We’ll start with demand forecasting in a traditional supply chain. However, we could just as easily be talking about biotechnology manufacturing or hospital demand of vaccines at hand at any given location. Typically, we extrapolate demand. Then we observe the relationships between independent and dependent variances such as previous sales and future demand. Next, we apply internal data, past trends, and maybe customer signals (inputs). There is just one problem. COVID came and crippled this conventional demand-forecasting process.

Today, these areas are becoming more efficient by using sophisticated analytical approaches, with collaborations across multiple functions, channels, and suppliers. But guess what? It’s still not working. Healthcare and biotechnology companies required a new strategy. First, they tried the more traditional approaches to maximize value, including:

  • Focusing on employee safety and operational continuity
  • Improving productivity and performance management
  • Increasing asset utilization and efficiency (whether it’s beds turnover or sterilizing medical equipment and instruments)
  • Improving quality in day-to-day operations
  • Optimizing workforce management

These approaches saw some thin benefits but not the 10x returns that were expected. Then they took a page from the Amazon and Apple playbook. Amazon has methodically taken control of its whole supply chain.

  • Consumer side: amazon.com, amazon fresh, kindle, whole foods
  • Seller side: amazon.com marketplace, amazon shipping
  • Enterprise side: amazon web services, EC2 (processing), amazon cloud drive, AWS marketplace, S3 (storage)
  • Entrepreneur side: amazon publishing, amazon flex (use your vehicle to deliver packages), amazon studios (new film series)
  • Amazon prime air: drones deliver 5-30lbs in 30min or less. On January 6, Amazon bought another 11 Boeing 767-300 planes
  • Amazon’s transportation fleet: now over 30,000 amazon branded vehicles and another 20,000 branded trailers

Amazon wants to own it all. The ability to control demand makes you curious, but the desire to manage your supply chain is more interesting. This concept also played out with Apple. Apple recently dropped Imagination Technologies. Previously, imagination was responsible for designing graphics processing units, the type used in Apple in products like the Apple iPhone. Apple plans to create its internal capabilities within the next 15months.

Biotechnology companies started to pay attention and have been leveraging this to control their supply chains, concentrating on production manufacturing for scale.

  • Pfizer and its German partner BioNTech, made 120 million doses in the U.S. within the first quarter
  • Aurinia Pharmaceuticals and Lonza have expanded their exclusive manufacturing relationship.
  • L’Oréal signed a leasing deal with Micreo, a biotech firm specializing in bacteria
  • Estée Lauder Companies announced a collaboration with biotech firm Atropos Therapeutics to explore lab-made ingredients

These examples highlight strategy movement to take ownership of traditional supply chains that were solely supplier operated and controlled.

Biotech investments point to the future

A great way to better understand innovation in healthcare and life sciences is to follow the money. Where are the venture capital deals? Where did top indications secure Series A funding? Who are the moves in these deals? We’ll focus on  2019 for data consistency; let’s get into it!

Where the top mind believe value lives (investments):

  1. Biopharma $15.6B
  2. Health tech $7.5B
  3. Dx Tools (medical diagnostics), which combine next-generation sequencing and artificial intelligence and computational resources – $4.4B
  4. Medical Devices $4.9B

What are the top indications to be funded?

  1. Oncology
  2. Platform
  3. Neurology
  4. Orphan/rare disease
  5. Anti-infective: to prevent or treat infections; they include antibacterials, antivirals, antifungals, and antiparasitic medications

In biopharma, who’s the most active (U.S. and Europe, 2018-2019)?

  • Alexandria, 42 deals
  • G.V. Corporate, 17 deals
  • Novartis, 16 deals
  • Pfizer, 13 deals
  • J&J, 12 deals
  • AbbVie, 9 deals
  • Merck, 7 deals

Which indication areas had the highest valuations?

  1. Cardiovascular
  2. Orthopedic
  3. Imaging
  4. Neurology
  5. Ophthalmology

Who’s the most active corporate healthcare investor?

  • BlueCross BlueShield
  • Alphabet
  • Echo
  • Philips
  • Merck
  • Tempus

We also saw a lot of movement in Series A deals. I enjoy looking at these acquisitions and takeovers targets to understand better how these innovative companies fit view themselves in the bigger picture. Where are they investing, and likewise, where are they divesting? Here are several of the movers the caught my eye.

  • AlizePharama, France, $82M in funding, specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer
  • Anthos Therapeutics, Cambridge, MA, stage II trials for some innovative therapies for high-risk cardiovascular patients
  • ArsenalBio, France, cell therapy, picked up $85M in round 1. Interestingly, even the University of California is a named investor in their Series A funding round.
  • Elevatebio, Mass, Cell and gene therapy, two years old and just raised $170M. They focus on the development and manufacturing of a specific type of therapeutic approach.
  • Talaris therapeutics, Louisville, KY and Boston, MA, IN 2019 they picked up $100M, then another $115M in Oct of 2020, crossing into phase III trials for crossed the Phase III with its lead drug, FCR001 –to prevent rejection of the donated organ by reducing infections
  • Passagebio, Philadelphia, PA, focusing on genetic medicines for rare monogenic central nervous system disorders. They picked up more than $200M in 2019 and recently went IPO, now with a market cap of $1.15B.
  • Mirum Pharmaceuticals, Foster City, CA, to developing drugs for rare liver diseases. Founded in 2018, now listed on Nasdaq with 604M in market cap.

Digital twins land on your doorstep

Patient value, intelligent systems, empowered workforces, and digital twins are starting to drag energy from the early adopters in life sciences.

Patient value is being pushed for healthcare outcomes and better patient experiences. Intelligent systems leverage context, real-time and secure patient data moving from systems of records to systems of insights and engagement. The empowered workforce is using digital experiences to drive culture and employee and patient behavior changes.

The most interesting is the digital twins. A digital twin is a concept first coined by Dr. Michael Grieves in 2002. Interestingly enough, NASA first used the concept in space exploration. It’s the first concept to connect the physical and digital worlds.
A digital twin is the generation of digital data to represent a physical object. It sounds very 2030; it’s not. Allow me to explain; the concept, while not named, has been around for a while.

  • Construction: used to model bridge structures and conduct force modeling
  • Energy: leverages this technology to simulate wind conditions for wind turbines
  • Offshore rigging: combines models with wave energy to model wave energy harvester system platforms to model motion of floats
  • Manufacturing: has been applying automotive car simulations and transforming them from models into real cars for what seems like forever

It’s only recently that healthcare can finally get on the wagon and start to apply this technology.

  1. Representing the action of a therapy
  2. Modeling longitudinal biomarkers
  3. Patient-specific behavior predictions
  4. Simulation of optimization drug-dosing regimens
  5. Replacement of bench and animal tests
  6. Optimize product drug design, manufacturing, and even packaging
  7. Population-specific predictions of cardiotoxicity for arrhythmias, anticoagulant, and heart failure medications
  8. Novel drug delivery mechanisms for biologics
  9. Medical device designs, e.g., minimally invasive heart valves
  10. Precision electrical neuro-stimulation therapies

The challenge is that biotechnology companies are often limited to only a simple 1D model’s cellular level. This can make translating these principles into a human body difficult.

Combining digital twins and prediction models has high-potential implications for patients. Predicting the outcome of prescription drugs by applying machine learning to model lifestyle choices makes patient decisions for medication adherence and choosing a healthy lifestyle very obvious. It’s not just the technologies that are ready for this innovation; patients are ready too. Let’s move away from this one-size-fits-all dosing approach and pivot into a new paradigm of stratifying patients into groups with similar genetic, environmental, and physiological factors. Using digital twins, we can get there.

The U.S. stimulus package, under the Health Information Technology for Economic and Clinical Health Act (the HITECH Act), has earmarked US$1.2 billion for the development of healthcare technology across the U.S.
Maybe digital twins should only live within the manufacturing world? Or perhaps there are just a few of us believers that believe innovation can spans industries.

Driving innovation for patients with medical research

Medical research is pushing new ideas fast into healthcare.

These ideas need a landing place to be discussed, designed, modeled, and experimented with before reaching patients. This is where innovation labs start to become significant. There are hundreds of outstanding examples of world-class incubators dedicated to enabling patients. I pulled together some of the most exciting innovation labs on the fridge connecting medical research with patient outcomes.

  • A.I. Innovation Lab: Novartis and Microsoft are combining data sets and A.I. solutions. They tackle the most demanding computational challenges in life sciences and use machine learning for personalized treatments for patients with related macular degeneration (eye disease) to prevent irreversible vision loss.
  • Health2047:  this is the innovation arm of the American Medical Association (AMA). They focused on chronic care, healthcare value, and physician productivity. Two impressive projects are the First Mile Care and Akiri. First Mile care – personalized support for prediabetes, offering access to coaching, tools, and resources to live healthier. Akiri – network as a service health data platform (previous was called health2047 Switch), focuses on safe access to information for patients, physicians, providers, pharma, and other healthcare enterprises.
  • VSP Global Innovation Center: recently founded in 2020, is dedicated to getting eye care and eyewear to the world. They promise to deliver eye care for their members. A member that has reached nearly 90 million in their global network. The innovation center has delivered two fascinating projects, blue light, and sustainability effort. VSP blue light-reducing eyewear to address digital eye strain and spearheading sustainability efforts to bring new materials to the market.
  • GSK Warren Innovation Lab Suites and Digitisation Lab  – GSK, based out of the U.K. with innovation multi-labs. The Warren innovation lab is located in New Jersey and has consumer panelists testing products and performing shopper science. Open Lab is based in Tres Contos, Spain, and brings together scientists and academics to tackle topics like malaria and T.B. leveraging GSK’s resources and networks. At the GSK Stevenage Bioscience Catalyst campus, they offer space and partner with early-stage biotech startups to commercialize their technology. Also, they have an R&D Open Lab for African NCDs (non-communicable diseases) like cancer and diabetes in Africa
  • Center for Innovation (CFI): located in the Mayo Clinic, started in 2008. I love their tagline, “Think big, start small, move fast.” The Innovation Exchange is a Mayo Clinic platform for members to access scientists, facilities, and their network focusing on greater patient access.
  • FUSE: is led by Cardinal health and integrates engineers with medical professionals and digital design experts. MedSync Advantage is a web-based in-house developed tool focused on pharmacists for medical synchronization to simplify patient prescription fulfillment.
  • The Innovation lab: is the child of AARP with a passion for health, wealth, and self.  The Embleema platform allows rare disease patients to own and share their data. Ianacare, based in Boston, is a platform to enable caregiver coordination. Community Connections launched in March of 2020 addresses social isolation facing seniors amid the COVID-19 pandemic. This powerful platform helps community members receive emotional, financial, and physical support.

After reading all the fantastic innovation lab stories and learning of the new partnerships happening today, I came to a single determination; we still care about the patient.

Payers and providers are identifying new value

Traditionally, payers and providers stayed in their lane. They had an overlap on occasion, but that was infrequently and often temporary. Payer and provider partnerships in 2020 were significant. We see a trend of coopetition. Unlikely, players realize they need to partner to increase their environmental fitness.

  • BCBS of California acquires a 2,700 physician group
  • CVS-Aetna open ~1000 drive through COVID-19 testing sites in May as part of its MinuteClinic expansion strategy. Today that has expanded to over 4800 CVS test sites
  • Optum Acquires post-acute care management platform Navihealth
  • Partners in Primary Care, the Humana-owned medical group, opens 20 new primary care centers.
  • Independence Blue Cross and CHOP enter a 5-year agreement to expand value-based care initiatives
  • Cigna partnered with Spectrum health of Michigan’s health plan. They prioritize health and increase provider access
  • BCBS of North Carolina incentivizes primary care providers with advanced, lump-sum payments to participate in BCBS’s value-based care program in 2021.

It’s evident from the payer and provider partnerships that something has changed from the days of the past. There is a renewed sense of urgency. The timeline has been compressed. Ideas that months or years ago were unheard of now are the discussion starters at leadership meetings. Unlikely partners are finding common ground by identifying shared objectives. What we’re experiencing in the healthcare ecosystem is the first private step towards healthcare interoperability.

The quiet transformations affecting health and life sciences

Innovation, disruption, and change lead CIOs’ minds as we explore the future of healthcare and life sciences.

The “Advancing and Enhancing Patient Care” panel was insightful and spanned topics such as innovations with care management, health-based investments, and connecting medical research to life-saving innovations. The panel discussion was lively, and as a result, much was covered. There was also a lot that I didn’t have time to cover within our limited timeframe. I want to introduce new insights; I didn’t have time to share them today fully.

The earlier pioneers in life sciences

New technology is reaching far beyond the bill and paperwork. Artificial intelligence and advanced analytics investments will enable the more intelligent use of multi-sourced data. This newly created data can help fuel clinical trials and accelerate research and development initiatives in the labs. Innovation is driving change in how we interact with patients.

  1. Remote patient monitor
  2. Start drug delivery systems
  3. Biometric trackers
  4. Ingestible sensors
  5. Medication adherence
  6. Diseases management apps

We’re hopeful that the 21st Century Cures Act will accelerate interoperability and patient access. This is a decisive step towards making the theory of continuum of care a reality. The recent MyHealthEData initiative promises to enable better access to patient’s medical information to promote better decision making. The Medicare Blue Button 2.0 initiative has solid traction and over 1,100 organizations already involved spanning 3,000 developers dedicated to making a change in patients’ access. This is compounded with the Patient Access API, which required health insurance exchanges to allow patient access to data through third parties, which went into effect on January 1, 2021.

There still are significant obstacles to providing seamless care, akin to a one-click amazon buy button. We’re not there yet. How will access to video CT scans be provided? To what device will patients download their MRI images? Who’s supporting this bandwidth? In the haste to introduce new technology, software companies forget about their customer: healthcare forgets about the patient experience. We can do better. Connectivity is the answer.

Italy has already figured this out. In Italy’s Lombardy Region (near Milan), the Agency for Innovation and Procurement (ARIA) has created a digital information hub integrating into a single platform more than ten years of health data for 10 million people living in the region. This sets an excellent foundation for virtualized care.

Peter Nichol Recognized as 2021 Top BRM by the BRM Institute

Peter B. Nichol was recognized as a 2021 Top BRM on February 9, 2021 by the BRM Institute.

Each year’s Top BRM list is revealed during #BRMWeek in February. BRM Institute’s global BRM community recognizes the top BRMs that have achieved success through their BRM efforts, strengthened the global BRM community and BRM discipline, enriched lives through excellence in BRM within their organizations, and contributed to the community on a local, national, and global level.

The BRM Institute’s global BRM community recognizes the top BRMs that have achieved success through their BRM efforts, strengthened the global BRM community and BRM discipline, enriched lives through excellence in BRM within their organizations, and/or contributed to the community on a local, national, and global level.

The 2021 Top BRM awards were evaluated based on the following major criteria:

Overall Impact:

  • Explain the impact the BRM has contributed to others around the globe!
  • Share the outstanding accomplishments the BRM has delivered
  • Highlight the amazing organizational accomplishments the BRM has delivered including notable contributions, improvements, discoveries, how they have demonstrated the BRM Code of Conduct, etc.

Leading with Purpose:

  • Bring more personal purpose in the workplace.
  • Identify the convergence of the personal and organization purpose to lead towards happier individuals, stronger relationships and durable communities.
  • Demonstrate how the BRM satisfied their personal or organizational purpose through their work.

Delivering Value:

  • Articulate the value delivered by the BRM engagement
  • Quantify the value realized through BRM organizational empowerment
  • Explain the impact of the value delivered through the BRM’s efforts.

Peter Nichol is a highly respected executive, BRM, and passionate evangelist for the BRM community. As a BRMP®, CBRM®, MBRM®, he is a change champion and has fully embraced the role, capability, discipline, and philosophy of the BRM Institute to achieve powerful results.

Peter is a positive voice among the BRM community. He is a member of the Value-Focused Organization Working Group, collaborating internationally with fellow BRM Institute leaders to amplify value. He was also elevated into the Vice-Chair role of the BRM Institute’s Executive Council (BEC), an advisory team comprised of executive-level individuals from leading organizations from around the globe, with a vision to advance the BRM discipline.

Peter has led businesses through complex changes, including the adoption of data-first approaches for portfolio management, data, analytics, lean six sigma for operational excellence, departmental transformations, process improvements, cloud migrations, maximizing team performance, designing new IT operating models, digitizing platforms, leading large-scale mission-critical technology deployments, product management, agile methodologies, and building high-performance teams. Peter is also a 4x author, MIT Sloan and Yale School of Management speaker, an avid blogger with hundreds of articles on BRM value, innovation, data science, artificial intelligence, and blockchain.

___

“This year’s Top BRM winners are recognized as BRMs within the global community who embody the true spirit of the BRM discipline. Every year, I am blown away by the stories of leading BRM professionals’ significant achievements and how their efforts have strengthened the network of relationships that is the single, global BRM community.

Your tireless passion and devotion to impacting others through excellence in BRM contribute to more sustainable communities on a local, national, and global level. Congratulations on being awarded a Top BRM of 2021 and thank you for doing the hard work to create positive change in the world!” — Aaron Barnes, CEO BRM Institute

___

“As a Master BRM, I am grateful to play a part in shaping the future of the BRM discipline into a single, global BRM community. Whether you’re officially called a business relationship manager, project manager, or agile practitioner, or have another title, the most important part of your role likely involves people. Leaders know that growing, fostering, and maturing cross-functional relationships that embrace an outside-in mindset is are the single most significant contributor to organizational success.

Artificial intelligence, machine learning, and cloud-first technologies are vital enablers, that’s true. However, if everyone is applying AI, everyone is using ML, and most companies are generating automation gains through cloud-first initiatives, then what is the differentiator between these companies?

The difference comes down to people—specifically the relationships those leaders develop. People are the number drivers of quantified business value. I’m excited to launch my 4th book in 2021 titled, Leading with Value. This book directly taps into how leaders quantify and articulate business value. This year will be another challenging year, and I’m confident we can tackle the challenges together as a single, global BRM community!” — Peter B. Nichol

References

BRM Institute. (2021). 2020 Top BRMs. https://brm.institute/2021-top-brms/

Leading With Value

February 9, 2020 — Peter Nichol published his 4th book, Leading with Value: How to Effectively Communicate Business Value.

In Leading with Value, author Peter B. Nichol provides access to secrets of how the best and most innovative companies tackle business value. His unique experience as a software engineer, architect, project leader, and CIO all synergize to provide you with clear, crisp, and actionable insights on how to capture and communicate business value. Based on his experience as a CIO, author of four books, and a data-science expert, Nichol captures the missing key for leaders struggling to quantify what impact they make and why it matters.

BUY ON AMAZON

BUY ON DATASCIENCECIO – AUTHOR SIGNED

Think Lead Disrupt

January 8, 2020 — Peter Nichol published his 3rd book, Think Lead Disrupt: How Innovative Minds Connect Strategy to Execution.

In Think Lead Disrupt, author Peter B. Nichol provides insights into how innovators can continually redesign products, services, and experiences in new and unique forms. Innovative companies don’t just appear. These disruptive companies evolve as a result of individual ideas, beliefs, and values. Individuals working together transform companies with original ideas. Nichol illuminates the mindset of innovative executives and explores how ideas lead to disruption. Based on his experience as a CIO, as the author of three books, and as a digital expert, Nichol captures how you can be part of the idea revolution.

BUY ON AMAZON

BUY ON DATASCIENCECIO – AUTHOR SIGNED